{"id":"4ff490d1d9f9","type":"article","url":"https://hartvaat.nl/2018/07/14/ldl-verlaging-en-cv-events-met-pcsk9-remmers-meta-analyse-van-gerandomiseerde-tr/","title":"LDL-verlaging en CV-events met PCSK9-remmers: meta-analyse van gerandomiseerde trials","title_en":"Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration.","category":"cholesterol","category_label":"Cholesterol","professions":["apotheker","cardioloog","internist"],"tags":["enlicitide","ezetimibe","farmaco-economie","figaro-dkd","gepersonaliseerde-geneeskunde","ldl-cholesterol","lipidenverlaging","niet-statine-therapie","ouderen","pcsk9-remmers","pcsk9-remmers-nieuwe-generatie","secundaire-preventie","select-trial"],"journal":"European heart journal","doi":"10.1093/eurheartj/ehx450","source_url":"https://doi.org/10.1093/eurheartj/ehx450","authors":["Brian A Ference","Christopher P Cannon","Ulf Landmesser","Thomas F Lüscher","Alberico L Catapano","Kausik K Ray"],"significance":8,"published":"2018-07-14","source_date":"2018-07-14","image":"","kennis":["https://hartvaat.nl/kennis/lipiden/omega3-vetzuren-cardiologie/","https://hartvaat.nl/kennis/lipiden/ldl-cholesterol-mechanisme/"],"congress":"","summary_en":"This meta-analysis quantified the relationship between LDL cholesterol reduction with PCSK9 inhibitors and cardiovascular event reduction, confirming proportional benefit consistent with the statin trials. The analysis strengthened the evidence that the mechanism of LDL lowering is less important than the magnitude of reduction.","created":"2026-07-03T10:27:22Z","updated":"2026-07-03T13:26:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Meta-analyse die het verband kwantificeerde tussen LDL-verlaging door PCSK9-remmers en cardiovasculaire events. Bevestigt proportioneel voordeel ongeacht het middel.","abstract_original":""}